Suramin interaction with human alpha-thrombin: inhibitory effects and binding studies.
Suramin is a hexasulfonated naphthylurea commonly used as antitrypanosomial drug and more recently for the treatment of malignant tumors. Here we show that suramin binds to human alpha-thrombin inhibiting both the hydrolysis of the synthetic substrate S-2238 (IC50 = 40 microM), and the thrombin-induced fibrinogen clotting (IC50 = 20 microM). The latter is completely reversed by albumin (30 mg mL(-1)) suggesting that, at therapeutic concentrations, suramin is unable to affect alpha-thrombin activity in the plasma. Kinetic analysis showed that suramin acts as a non-competitive inhibitor decreasing Vmax without changing the Km for S-2238 hydrolysis. Calorimetric studies revealed two distinct binding sites for suramin in alpha-thrombin. In addition, circular dichroism studies showed that suramin causes significant changes in alpha-thrombin tertiary structure, without affecting the secondary structure content. Interaction with alpha-thrombin resulted in an increased fluorescence emission of the drug. Complex formation was strongly affected by high ionic strength suggesting the involvement of electrostatic interactions. Altogether our data suggest that part of the biological activities of suramin might be related to alpha-thrombin inhibition at extra-vascular sites.
Monteiro
Robson Q
RQ
Departamento de Bioquímica Médica, ICB/CCS, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil. robsonqm@bioqmed.ufrj.br
Campana
Patricia T
PT
Melo
Paulo A
PA
Bianconi
M Lucia
ML
D002151:Calorimetry; D002384:Catalysis / Q000187:drug effects; D002942:Circular Dichroism; D006801:Humans; D007700:Kinetics; D015394:Molecular Structure; D011485:Protein Binding; D011487:Protein Conformation / Q000187:drug effects; D013498:Suramin / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology*; D013917:Thrombin / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism*; D017186:Titrimetry
D013498:Suramin; D013917:Thrombin